Response of Carcinoma-Associated Fibroblasts to Chemotherapy
Author Information
Author(s): Sonnenberg Maike, van der Kuip Heiko, Haubeiß Silke, Fritz Peter, Schroth Werner, Friedel Godehard, Simon Wolfgang, Mürdter Thomas E, Aulitzky Walter E
Primary Institution: Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology and University of Tuebingen
Hypothesis
The study investigates the influence of chemotherapy on carcinoma-associated fibroblasts (CAFs) and their potential impact on therapy outcomes.
Conclusion
CAFs exhibit a highly variable response to chemotherapy, influenced by cancer type and microenvironment.
Supporting Evidence
- Nine of 22 tumors showed a therapy-dependent reduction of stromal activity.
- Isolated CAFs showed little sensitivity to paclitaxel.
- Sensitivity of CAFs to cisplatinum was highly variable with a GI50 ranging from 2.8 to 29.0 μM.
- No somatic TP53 mutation was detected in any of the 28 CAFs from lung cancer tissue.
- Response to cisplatinum was not significantly associated with the genotype of TP53 nor Mdm2 and ERCC1 polymorphisms.
Takeaway
This study shows that the cells around tumors, called fibroblasts, react differently to cancer treatments, which can affect how well the treatment works.
Methodology
The study analyzed the response of CAFs to chemotherapy in vitro and in vivo using tissue sections and primary cultures from breast and lung cancer patients.
Limitations
The study's conclusions are limited by the small sample size and the retrospective nature of the analysis.
Participant Demographics
Patients included women with invasive breast carcinomas treated with neoadjuvant chemotherapy.
Statistical Information
P-Value
0.67
Statistical Significance
p=0.67
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website